Human Glucose dependent insulin releasing polypeptide,GIP ELISA Kit

Code CSB-E08484h
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Alternative Names
Gastric Inhibitory Peptide ELISA Kit; Gastric inhibitory polypeptide ELISA Kit; Gastric inhibitory polypeptide precursor ELISA Kit; GIP ELISA Kit; GIP_HUMAN ELISA Kit; Glucose dependent insulinotropic polypeptide ELISA Kit; Glucose-dependent insulinotropic polypeptide ELISA Kit; Incretin hormone ELISA Kit
Abbreviation
GIP
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates
Detection Range
12.5 ng/ml-200 ng/ml.
Sensitivity
2.5 ng/ml.
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Signal Transduction
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<15%      
Three samples of known concentration were tested twenty times on one plate to assess.  
Inter-assay Precision (Precision between assays): CV%<15%      
Three samples of known concentration were tested in twenty assays to assess.    
             
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human GIP in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)  
1:1 Average % 89  
Range % 85-95  
1:2 Average % 95  
Range % 91-103  
1:4 Average % 96  
Range % 92-100  
1:8 Average % 94  
Range % 89-98  
Recovery
The recovery of human GIP spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range  
Serum (n=5) 96 89-100  
EDTA plasma (n=4) 94 90-99  
             
             
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/ml OD1 OD2 Average    
11.43 0.063 0.062 0.063    
22.9 0.168 0.171 0.170    
45.7 0.389 0.405 0.397    
114 0.932 0.953 0.943    
200 1.580 1.625 1.603    
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

This Human GIP ELISA Kit was designed for the quantitative measurement of Human GIP protein in serum, plasma, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 11.43 ng/mL-200 ng/mL and the sensitivity is 7.14 ng/mL.

Citations

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

 Q&A
Q:

I have a technical question regarding products CSB-E08484h, CSB-E08119h, and CSB-E09207h.
How is the plate mapping for these kits? (How many wells for standard, controls, and samples)

A:

These 3 items are sandwich ELISA kits (double-antibody). For a 96T sandwich ELISA kit (double-antibody), we suggest you run duplicates for the standard. In this way, you can test 80 samples. We also suggest you run duplicates for the sample, and in this way you can test 40 samples. You can decide how many kits you need according to the number of your samples. If you run a pre-test, the number of samples you can detect in one kit will be less.

Target Background

Function
(From Uniprot)
Potent stimulator of insulin secretion and relatively poor inhibitor of gastric acid secretion.
Gene References into Functions
  1. The genetic variability of GIP gene is associated with coronary artery disease and it may play a role in the premature coronary artery disease in the Chinese Han population with type 2 diabetes. PMID: 29765988
  2. The ability of a truncated form of GIP, GIP(3-30)NH2, to antagonize the physiological actions of GIP in glucose metabolism, subcutaneous abdominal adipose tissue blood flow, and lipid metabolism in humans. PMID: 28667118
  3. GIP and PP plasma concentrations are lower in pancreatic cancer irrespective of the degree of glucose intolerance as compared to Type 2 diabetic patients and healthy controls. PMID: 28027898
  4. Evening postprandial insulin and GIP responses and insulin resistance declined by over 30% after three meals that limited daily carbohydrate intake to 30% compared to no such changes after three 60%-carbohydrate meals, an effect that was independent of pre-meal exercise. PMID: 27798656
  5. the stimulatory effect of IGF-1 on GIP promoter support the hypothesis of a functional growth hormone-igf-1-GIP axis PMID: 28179449
  6. decreased maternal 25OHD may be associated with decreased cord 25OHD and increased cord GLP-1 and GIP levels, which may be involved with the transfer of maternal glucose to the fetus PMID: 26650343
  7. Excess androgen activity might be a factor contributing to alter secretion of incretins in lean polycystic ovary syndrome (PCOS) women. However it could not be ruled out that it is also possible that increased GIP levels might induce hyperandrogenemia in PCOS. PMID: 26895276
  8. Our results might indicate an altered DPP4-incretin system and altered immunoregulation including a potentially dysfunctional GLP1(9)(-)(36) signaling in T1DM. PMID: 26434625
  9. Fasting GIP concentrations are higher in individuals with a history of cardiovascular disease (myocardial infarction, stroke) when compared with control subjects. PMID: 26395740
  10. Data suggest that high levels of blood glucose or AGEs (advanced glycation end products), as seen in hyperglycemia, reduce secretion of insulin by pancreatic beta cells via antagonism of GIP (gastric inhibitory polypeptide)/GIP receptor signaling. PMID: 26221611
  11. Data confirm that postprandial plasma levels of glucose-dependent insulinotropic polypeptide (GIP) and insulin (INS) are responsive to glycemic index of foods consumed; glycemic index of breakfast cereals regulate plasma postprandial GIP and INS. PMID: 25852025
  12. irisin and GIP might contribute to the development of polycystic ovary syndrome and may also represent novel polycystic ovary syndrome biomarkers PMID: 25029417
  13. Data suggest that postprandial blood levels of both GIP and insulin can be regulated by diet; here, inclusion of nopal/Opuntia/cactus (a functional food in traditional Mexican medicine) in breakfast reduces postprandial levels of GIP and insulin. PMID: 25132122
  14. phosphatidylinositol 3-kinase gamma has a role in insulin secretion induced by glucose-dependent insulinotropic polypeptide PMID: 25288806
  15. These novel results support the notion that the GIP-GIPR axis plays a role in the etiology of central obesity in humans PMID: 25324507
  16. Data from studies in healthy Japanese men suggest that plasma GIP levels in postprandial period are dose dependently increased by fat content of meals of ordinary size, despite the amount of additional fat being relatively small. PMID: 24507870
  17. Patients with idiopathic gastroparesis exhibit abnormal GIP levels. PMID: 23663508
  18. Beta cell connectedness is an inherent property of human islets that is likely to influence incretin-potentiated insulin secretion. PMID: 24018562
  19. Data suggest that postprandial plasma levels of glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP1) are increased after consumption of buckwheat crackers versus rice crackers in healthy and type 2 diabetic subjects. PMID: 23485142
  20. GIP induces an inflammatory and prolipolytic response via the PKA -NF-kappaB-IL-1 pathway and impairs insulin sensitivity of glucose uptake in human adipocytes. PMID: 23092914
  21. results indicate postprandial GIP secretion in early-phase after test meal in Japanese patients with type 2 diabetes was positively correlated with BMI, but not those with type 1 diabetes PMID: 22301939
  22. Hyperinsulinemia subjects with metabolic syndrome showed increased GIP secretion that could be responsible for the delayed glucagon suppression. PMID: 22391044
  23. Data suggest that reduced insulinotropic effect of GIP or GLP-1 (as in type 2 diabetes) can be induced in healthy subjects; this indicates that reduced incretin stimulation of insulin secretion results from insulin resistance/glucose intolerance. PMID: 22319034
  24. GIP reduces free fatty acid release from adipose tissue by inhibition of lipolysis or by increased reesterification. PMID: 22179810
  25. may have a pro-obesogenic action [review] PMID: 21815989
  26. Studies identified some potentially important additional C-terminal interactions of GIP with its N-terminal extracellular receptor domain. PMID: 21539943
  27. We report that the human GIP locus was differentially selected in East Asians about 8100 years ago based on the analysis of a nonsynonymous SNP (rs2291725). PMID: 20978139
  28. GLP-2, but not GIP, was found to stimulate the release of glucagon in patients with T1DM, suggesting a role for GLP-2 in the postprandial hyperglucagonaemia characterising individuals with T1DM PMID: 20580750
  29. These results suggest that Tyr/His(1) and Ile/Thr(7) of GIP/GLP-1 peptides confer differential ligand selectivity toward GIPR and GLP1R. PMID: 20799012
  30. We demonstrate for the first time that changes in insulin secretion after lifestyle intervention may be mediated via alterations in GIP secretion from intestinal K-cells PMID: 20200305
  31. No statistically significant association was observed between any of the single nucleotide polymorphisms of GIP analysed and type 2 diabetes in our population. PMID: 20673334
  32. GIP is expressed in and secreted from pancreatic islets and promotes islet glucose competence and also could support islet development and/or survival. PMID: 20138041
  33. a binding mode of GIP to GIPR in which the N-terminal moiety of GIP was sited within transmembrane helices (TMH) 2, 3, 5, and 6 with biologically crucial Tyr1 interacting with Gln224 (TMH3), Arg300 (TMH5), and Phe357 (TMH6). PMID: 20061446
  34. Substitution of Glu(3) in GIP with proline produces a novel dipeptidylpeptidase IV-resistant GIP antagonist which inhibits GIP-induced cAMP generation and insulin secretion with high sensitivity and specificity in vitro. PMID: 11820780
  35. activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway PMID: 12138104
  36. Mutation in promoter region of gip receptor gene are unlikely to underlie GIP-dependent Cushing syndrome. PMID: 12530694
  37. Elevated plasma GIP levels are correlated with hyperinsulinemia in the impaired glucose-tolerant state, whereas type 2 diabetes is associated with a failure to secrete adequate amounts of GIP. PMID: 15220248
  38. bombesin and nutrients additively stimulate GIP release from GIP/Ins cells. PMID: 15383372
  39. Results describe the solution structure of GIP(1-30)amide, the major biologically active fragment of glucose-dependent insulinotropic polypeptide. PMID: 15522230
  40. GIP augments glucose-stimulated insulin secretion and acts as an endogenous inhibitor of gastric acid secretion--REVIEW PMID: 15533777
  41. GIP stimulates insulin secretion by potentiating events underlying membrane depolarization and exerting direct effects on exocytosis. PMID: 15955806
  42. The relationship between insulin resistance and the insulin secretion to GIP suggests that beta cell secretory function in response to different stimuli increases adaptively when insulin sensitivity is diminished, as in gestational diabetes. PMID: 16010522
  43. GIP is rapidly degraded into inactive metabolites by the enzyme dipeptidyl-peptidase-IV. (review) PMID: 16142014
  44. protein kinase B, LKB1, and AMP-activated protein kinase have roles in activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes PMID: 17244606
  45. study identified a splice site mutation of the Glucose-dependent insulinotropic polypeptide (GIP) gene which results in a truncated protein and provides evidence for association of GIP receptor genotype with cardiovascular disease PMID: 17624916
  46. physiologic role for GIP in lipid homeostasis and possibly in the pathogenesis of obesity. PMID: 18054552
  47. concomitant expression of Pax6 and Pdx1 is important for glucose-dependent insulinotropic polypeptide expression PMID: 18593849
  48. GIP secretion is blunted after the biliopancreatic diversion only in diabetic patients, suggesting a role in insulin resistance and diabetes. PMID: 19229515
  49. GIP may mediate the attenuated glucose-stimulated insulin response after exercise/diet interventions PMID: 19351807
  50. Inhibition of apoptosis by GIP is mediated via a key pathway involving Akt-dependent inhibition of apoptosis signal-regulating kinase 1, which subsequently prevents the pro-apoptotic actions of p38 MAPK and JNK. PMID: 19748889

Show More

Hide All

Subcellular Location
Secreted.
Protein Families
Glucagon family
Database Links

HGNC: 4270

OMIM: 137240

KEGG: hsa:2695

STRING: 9606.ENSP00000350005

UniGene: Hs.1454

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X